HLB
HLB Co., Ltd. is a South Korean biopharmaceutical and healthcare enterprise that specializes in the development, clinical testing, and commercialization of targeted cancer therapies. The company operates through primary business segments including Biopharmaceutical Research, Healthcare Products, and Industrial Engineering. Its principal future revenue drivers stem from commercial sales of pharmaceutical candidates, targeted oncology treatments, licensing agreements, and healthcare device distribution. HLB Co., Ltd. holds a prominent market position in the South Korean biopharmaceutical industry, focusing heavily on its targeted anti-cancer drug candidate rivoceranib for various oncology indications. The enterprise conducts clinical development trials across global healthcare markets, collaborating with international research institutions and pharmaceutical partners. The company focuses on securing regulatory approvals for its oncology pipeline, expanding global licensing agreements, and advancing biopharmaceutical manufacturing operations. HLB Co., Ltd. is headquartered in Seoul, South Korea, and its common stock is publicly listed and traded on the KOSDAQ market of the Korea Exchange.
13 of the funds FundTelligence covers report a position in HLB.
- Legal name
- HLB Co. Ltd.
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 13
Funds holding HLB
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.05 % (full portfolio disclosed, September 2026)
- Lannebo Emerging Markets — Lannebo · 0.04 % (full portfolio disclosed, June 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.04 % (full portfolio disclosed, December 2025)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.03 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.02 % (full portfolio disclosed, July 2026)
- Storebrand Emerging Markets — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- SEB Emerging Markets Exposure — SEB · 0.02 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 13 funds holding it.